U.S. President Donald Trump’s announcement of his intention to reduce funds to numerous government departments has many worried. One primary target of the cuts is the National Institutes of Health (NIH). Attempts were also made to repeal the Affordable Care Act (ACA) (often referred to as Obamacare) though a revolt amongst the republican party saw … [Read more...] about Trump to remove critical funds from the CDC?
Swiss pharmaceutical company Roche is conducting consistent legal battles against smaller companies to dissuade them from entering the market of breast cancer medication reports The Wire. They claim that this has, in effect, granted Roche a monopoly over the biosimilars market, with an emphasis on the breast cancer medication trastuzumab. As a … [Read more...] about Biosimilars and the trastuzumab controversy
Modern science is in an arms race with mosquito borne disease and climate change is bringing the mosquito threat to the doorsteps of yet more nations. Recent headlines are placing emphasis on the views of the new President of the United States Donald Trump and many of his cabinet appointees, rejecting the scientific consensus on climate change. … [Read more...] about Mosquito-borne illness in 2017
A drug trial for a Merck & Co Inc. (MSD) medication verubecestat has been stopped because it was very unlikely to show a significant difference in Alzheimers disease progression compared to a placebo control. This was a phase III clinical trial in patients with early dementia. The setback comes after months of positive media attributed … [Read more...] about Failed trials for Alzheimer’s may mean a key theory is wrong
Worrying reports have surfaced regarding Trump’s new healthcare secretary and his views on anti-vaccination. Tom Price now heading a department backed by a budget of over $1 trillion USD, is a member of a group that describes mandatory vaccination as “equivalent to human experimentation”. The group itself, the Association of American Physicians and … [Read more...] about Donald Trump’s stance on anti-vaccination
The first sentence of the official press release for the new UN report on access to medicines captures all the problems with the report, probably inadvertently. Here is the monster sentence Whether it’s the rising price of the EpiPen, or new outbreaks of diseases, like Ebola, Zika and yellow fever, the rising costs of health technologies … [Read more...] about Hype for UN’s report on access to medicines is confused and contradictory
Updated on the 27th of June 2016 -- this is a re-edited version of a post we originally put on the site in December 2015 I lied to the company that runs my gym recently. I like the gym and, although I have limited contact with them, the managers seem competent and nice enough. They sent me a market research survey and my lies on it are … [Read more...] about The dangerous unreliability of quantitative market research seen in Brexit
A comment piece by the redoubtable Ellen t'Hoen in this week's Lancet illustrates exactly the bind that the pharma industry finds itself in when trying to improve access to medicines in poorer countries. The piece reviews a judgement by the Indian Patent Office to reverse an earlier decision and grant the U.S. company Gilead a patent for Sovaldi … [Read more...] about The pharma industry’s access Catch-22
Hyderus undertakes healthcare research in Argentina Hyderus was recently commissioned to undertake research into the market for innovative oncology products in Argentina, which is an emerging country in terms of its healthcare status on the world stage. An in-depth research project was undertaken, which looked at the Argentine health system, … [Read more...] about Patagonia/Argentina – what’s our connection?
Recent controversy about access and IP Will India risk the wrath of many of its trading partners by issuing more compulsory licences to give access to innovative medicines? The question has flared to life again over the past few weeks. In early March, US trade groups sounded triumphal: India had assured the Americans that it would respect the … [Read more...] about What India will really do about access to innovative medicines